Relation between diagnoses on severity, sick leave and loss of job among patients with occupational hand eczema

Cvetkovski, RS; Rothman, Kenneth J.; Olsen, Jørn; Mathiesen, B; Iversen, Lars; Johansen, Jeanne Duus; Agner, Tove

doi:10.1111/j.1365-2133.2005.06415.x

Cited by 190 publications

(197 citation statements)

References 23 publications

Supporting

Mentioning

161

Contrasting

Unclassified

Order By: Relevance

“…Widespread hand dermatitis on initial examination was found to be the greatest factor for a poor long-term prognosis in another study [Meding et al 2005]. In addition, many skin disorders, including contact dermatitis, have been shown to have a significant impact on quality of life [Kadyk et al 2003;Cvetkovski et al 2005;Fowler et al 2006;Lan et al 2008]. …”

Section: Discussionmentioning

confidence: 99%

Evaluation of dermatitis among sanders in a furniture manufacturing plant.

2013

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Evaluation of dermatitis among sanders in a furniture manufacturing plant.

2013

View full text Add to dashboard Cite

“…Widespread hand dermatitis on initial examination was found to be the greatest factor for a poor long-term prognosis in a third study [Meding et al 2005]. In addition, many skin disorders, including contact dermatitis, have been shown to have a significant impact on quality of life [Kadyk et al 2003;Cvetkovski et al 2005;Fowler et al 2006;Lan et al 2008].…”

Section: Statistical Analysesmentioning

confidence: 99%

Evaluation of contact dermatitis among ink ribbon manufacturing employees - New York.

2011

View full text Add to dashboard Cite

“…4 In addition, hand eczema has been shown to be a major cause of prolonged sick leave and has been reported to lead to job loss. 5 Patients with CHE have a poor prognosis; it is a self-perpetuating condition with a long-lasting and chronically relapsing course. 6 No licensed treatment options are available for these patients.…”

Section: Description Of the Underlying Health Problemmentioning

confidence: 99%

Alitretinoin for the treatment of severe chronic hand eczema

Paulden

Rodgers

Griffin

et al. 2010

Health Technol Assess

View full text Add to dashboard Cite

This paper presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of alitretinoin for the treatment of adults with severe chronic hand eczema refractory to topical steroid treatment in accordance with the licensed indication, based upon the evidence submission from Basilea Pharmaceuticals Ltd to the National Institute for Health and Clinical Excellence (NICE) as part of the single technology appraisal process. The clinical evidence came from a single placebocontrolled randomised controlled trial of daily treatment with alitretinoin for 12-24 weeks, with follow-up for a further 24 weeks, in patients with severe chronic hand eczema (CHE) unresponsive to topical steroids. A statistically significantly greater proportion of patients using alitretinoin achieved the primary end point of clear or almost clear hands by week 24 than did those with placebo. Dose-dependent headache was the most commonly reported adverse event in patients treated with alitretinoin. Serious adverse events were rare, but alitretinoin was associated with increases in both total cholesterol and triglycerides, which has implications for risks of future cardiovascular events. The manufacturer submitted a de novo decision analytic model to estimate, over a time horizon of 3 years, the cost-effectiveness of alitretinoin versus the other relevant comparators identified by NICE. In response to the points of clarification put to it by the ERG regarding the initial submission, the manufacturer provided additional evidence and a revised decision analytic model with a 'placebo' arm. In the manufacturer's original DOI: 10.3310/hta14suppl1/06Alitretinoin for the treatment of severe chronic hand eczema 40 submission to NICE, the base-case incremental cost-effectiveness ratios (ICERs) reported for alitretinoin were £8614 per quality-adjusted lifeyear (QALY) versus ciclosporin, -£469 per QALY versus psoralen + UVA (with alitretinoin dominant) and £10,612 per QALY versus azathioprine. These ICERs decreased as the time horizon was extended in sensitivity analyses. In patients with hyperkeratotic CHE and in women of child-bearing potential, the ICER remained below £20,000. When the health-related quality of life (HRQoL) values used in the model were replaced with those derived from an alternative study, these ICERs increased significantly (to £22,312 per QALY for alitretinoin versus azathioprine). In the revised model, alitretinoin was reported to have an ICER of £12,931 per QALY gained versus supportive care (placebo). However, the model underestimates the costs of treatment associated with alitretinoin.

show abstract

Relation between diagnoses on severity, sick leave and loss of job among patients with occupational hand eczema

Abstract: Occupational ICD and AD appear to be strongly associated with severity of OHE. AD and severity of OHE were independently associated with prolonged sick leave. Having a food-related occupation appears to be associated with increased risk of loss of job.

Cited by 190 publications

References 23 publications

Evaluation of dermatitis among sanders in a furniture manufacturing plant.

Evaluation of dermatitis among sanders in a furniture manufacturing plant.

Evaluation of contact dermatitis among ink ribbon manufacturing employees - New York.

Alitretinoin for the treatment of severe chronic hand eczema

Contact Info

Product

Resources

About